Clinical Trial Update: A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial of LCAR-B38M BCMA-directed CAR-T cells in Chinese participants with relapsed or refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LCAR-B38M CAR-T cells (LCAR-B38M CAR-T cells)

Snippet

Sponsor: Nanjing Legend Biotech Co. | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED